SCHEMBL17755286

SCHEMBL17755286

CC(C)(C)OC(=O)NC(C)(C)c1n[nH]c2c(F)cccc12

nearest known ligand 0.38

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 14/20 0.38
EPHX2 P34913 2/20 0.37
SCN9A Q15858 1/20 0.37
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
PARP1 P09874 1/20 0.36
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17763199 0.88 EPHX2 (0.38) SSTR4EPHX2MEN1NPC1GAA
SCHEMBL17755072 0.85 CHEK1 (0.41) SSTR4EPHX2MEN1NPC1GAA
SCHEMBL19724842 0.79 SSTR4 (0.54) SSTR4
SCHEMBL16256019 0.79 SSTR4 (0.54) SSTR4
SCHEMBL31740695 0.77 SSTR4 (0.40) SSTR4PARP1
SCHEMBL19564989 0.76 LMNA (0.34) SSTR4PARP1
SCHEMBL19724776 0.76 SSTR4 (0.67) SSTR4
SCHEMBL17754963 0.76 SSTR4 (0.60) SSTR4
SCHEMBL22015380 0.76 SSTR4 (0.34) SSTR4PARP1
SCHEMBL14158304 0.75 TNKS (0.44) SSTR4PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368625-A1 PIPERAZINES Grünenthal GmbH (DE) 2025-12-04 US disclosed
EP-3218372-B1 MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS BOEHRINGER INGELHEIM INT (DE) 2020-05-20 EP disclosed
US-10577336-B2 Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-03-03 US disclosed
US-10183940-B2 Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-22 US disclosed
US-20170320838-A1 MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-11-09 US disclosed
US-20170320838-A1 MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-11-09 US disclosed
WO-2016075240-A1 MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-19 WO disclosed
WO-2016075239-A1 ARYL AND HETEROARYL-FUSED TETRAHYDRO-1,4-OXAZEPINE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170320838-A1 MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS SSTR4, SSTR1, SSTR3 SSTR4 1/4885EPHX2 3747/4885SCN9A 1489/4885
US-10577336-B2 Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists SSTR4, SSTR1, SSTR3 SSTR4 1/4885EPHX2 3747/4885SCN9A 1489/4885
US-10183940-B2 Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists SSTR4, SSTR3, SSTR5 SSTR4 1/4885EPHX2 2347/4885SCN9A 777/4885
US-20250368625-A1 PIPERAZINES SSTR4, SSTR5, SSTR2 SSTR4 1/4885EPHX2 4051/4885SCN9A 752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.